Project description
An off-the-shelf anti-cancer vaccine
Leveraging the immune system to fight cancer is a promising concept, but clinical success so far has been limited. The underlying reason is the presence of cancer stem cells (CSCs) that exhibit resistance and cause tumour recurrence. The EIC-funded MUTAVAC project proposes to generate a highly immunogenic version of IPVAC, an immunotherapy based on induced pluripotent stem cells generated with the antigens of CSCs. This cell-based therapy has the potential to serve in both prevention and therapy of cancers with CSC features. Importantly, this cell therapy can be scaled up for clinical use yet personalised to accommodate the unique characteristics of individual tumours.
Objective
The successful application of immune checkpoints inhibitors has modified the therapeutic strategies in several cancers but only 30% of patients will respond optimally to these therapies. One of the reasons for the failure of these therapies is the resistance of cancer stem cells (CSCs) leading to relapses long after the initial treatment. These cells are also resistant to conventional therapies via their quiescence and there are no targeted therapies available against them. The ambition of IPSIRIUS, a French biotechnology company, spinoff of INSERM and Paris Saclay University is to develop active cancer immunotherapy products based on the revolutionary induced pluripotent stem cell (iPSC) technology. IPSIRIUS developed first IPVAC, with the aim of leveraging patients immune system against a large panel of cancer antigens which are shared between iPSC and CSCs. With IPVAC, IPSIRIUS is developing a ground-breaking technology, having resolved all technical issues limiting cell-based therapies used for cancer. IPVAC is a safe, allogenic, off-the-shelf therapy, highly scalable using a versatile technology. This cell-based vaccination strategy showed efficacy in prophylactic and therapeutic settings against aggressive solid cancers with stemness features. The overall goal of the MUTAVAC project is i) to uncover the mechanisms of action of IPVAC, ii) to generate a highly immunogenic version of IPVAC, and iii) to design robust in vitro immunogenicity tests to predict immunogenicity of IPVAC and IPVAC-Mut in humans. With MUTAVAC project, IPSIRIUS will i) strengthen the scientific data on IPVAC to prepare its clinical development and leading to the open access publications and patents, ii) define a personalised medicine to propose efficient therapeutic cancer vaccine in patients with all HLA groups, iii) identify new targets for future cancer therapies, and iv) develop a technological platform to facilitate the development of the next-generation of cell therapies.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine oncology
- medical and health sciences medical biotechnology cells technologies
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.3.1 - The European Innovation Council (EIC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-EIC - HORIZON EIC Grants
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-EIC-2021-PATHFINDERCHALLENGES-01
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
75005 Paris
France
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.